January 24, 2017
Asit’s Phase II study of dust allergy treatment shows success
Asit biotech has completed Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 24, 2017
Abzena to issue ordinary shares
Abzena has made application to the London Stock Exchange for the admission of 715,772 new ordinary shares of £0.002 each (‘New Ordinary Shares’) to trading on AIM.
January 24, 2017
Short: Van Herk Investments announces 10.07% Shareholding in Ablynx
Van Herk Investments B.V. has become owner of more than 10% of Ablynx as it has crossed the 10% threshold and now…
January 24, 2017
ImmuPharma appoints new adviser
ImmuPharma has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect. ImmuPharma is a pharmaceutical…
January 23, 2017
Swedish Oasmia targets $16B worth US animal health care market
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.
January 23, 2017
Stada names new executive board member
STADA Arzneimittel AG has named Dr. Barthold Piening as a full Member of the Executive Board with effect from July 1, 2017.
January 23, 2017
Alliance Pharma reduces net debt, doubles revenue
Alliance Pharma’s revenue for 2016, driven by the acquisition of ex-Sinclair products in December 2015, could be more than double compared to the previous year.
January 23, 2017
Oxford Biodynamics in licencing deal with Singapor’s EpiFit
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.
January 23, 2017
Consort in equity raise by Atlas Genetics, funds subsidiary Bespak
Consort Medical, a single source drug and delivery device company, has participated in a further equity raise by Atlas Genetics Ltd.
January 23, 2017
Cellestis’s scientists on safety in new CAR architecture
Cellectis’s scinetists lead by Dr Alexandre Juillerat have designed a new CAR architecture that contains an integrated microenvironment sensor. Their work was recently published in a scientific magazine “Scientific Reports”.